For instance, in murine fibrotic NASH models, treatment with miR-223-3p mimic ameliorated activation of HSCs and fibrosis development through its NLRP3-targeted effect in KCs (106). The gene discussed is NLRP3; the disease is metabolic dysfunction-associated steatohepatitis.